SCHEMBL24118320

SCHEMBL24118320

C=C(CCNC(=O)c1ccc(F)c(Cl)c1)CC(=O)Nc1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ KCNQ3 O43525 1/20 0.47
▸ KCNQ2 O43526 1/20 0.47
▸ KCNE1 P15382 1/20 0.47
▸ KCNQ1 P51787 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ RHOC P08134 2/20 0.47
▸ RHOA P61586 2/20 0.47
▸ IDO1 P14902 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24117941 0.87 POLB (0.51) ALDH1A1POLBTP53MEN1KMT2A
SCHEMBL24117953 0.85 RHOC (0.50) ALDH1A1POLBTP53MEN1KMT2A
SCHEMBL24117910 0.83 RHOC (0.45) ALDH1A1POLBTP53MEN1KMT2A
SCHEMBL24118257 0.81 KCNQ3 (0.54) ALDH1A1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL24118071 0.78 POLB (0.54) ALDH1A1POLBMEN1KMT2ARHOC
SCHEMBL24118064 0.73 IDO1 (0.46) ALDH1A1POLBKCNQ3KCNQ2KCNE1
SCHEMBL24117930 0.72 CYP1A2 (0.49) ALDH1A1POLBTP53MEN1KMT2A
SCHEMBL19835598 0.72 HPGD (0.73) ALDH1A1POLBKCNQ3KCNQ2KCNE1
SCHEMBL6361467 0.71 KMT2A (0.61) ALDH1A1POLBKCNQ3KCNQ2KCNE1
SCHEMBL24117949 0.71 IDO1 (0.53) ALDH1A1POLBKCNQ3KCNQ2KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 ALDH1A1 144/4885POLB 1950/4885KCNQ3 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback